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Abstract: The clinical significance of copy number variants (CNVs) in 
congenital heart disease (CHD) continues to be a challenge. Although CNVs 
including genes can confer disease risk, relationships between gene dosage 
and phenotype are still being defined. Our goal was to perform a quantitative 
analysis of CNVs involving 100 well-defined CHD risk genes identified through 
previously published human association studies in subjects with anatomically 
defined cardiac malformations. A novel analytical approach permitting CNV 
gene frequency “spectra” to be computed over prespecified regions to 
determine phenotype-gene dosage relationships was employed. CNVs in 
subjects with CHD (n = 945), subphenotyped into 40 groups and verified in 
accordance with the European Paediatric Cardiac Code, were compared with 
two control groups, a disease-free cohort (n = 2,026) and a population with 
coronary artery disease (n = 880). Gains (≥200 kb) and losses (≥100 kb) 
were determined over 100 CHD risk genes and compared using a Barnard 
exact test. Six subphenotypes showed significant enrichment (P ≤ 0.05), 
including aortic stenosis (valvar), atrioventricular canal (partial), 
atrioventricular septal defect with tetralogy of Fallot, subaortic stenosis, 
tetralogy of Fallot, and truncus arteriosus. Furthermore, CNV gene frequency 
spectra were enriched (P ≤ 0.05) for losses at: FKBP6, ELN, GTF2IRD1, 
GATA4, CRKL, TBX1, ATRX, GPC3, BCOR, ZIC3, FLNA and MID1; and gains 
at: PRKAB2, FMO5, CHD1L, BCL9, ACP6, GJA5, HRAS, GATA6 and RUNX1. Of 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
4 
 
CHD subjects, 14% had causal chromosomal abnormalities, and 4.3% had 
likely causal (significantly enriched), large, rare CNVs. CNV frequency spectra 
combined with precision phenotyping may lead to increased molecular 
understanding of etiologic pathways. 
Keywords: congenital heart disease, copy number variation, genetics 
Structural congenital heart disease (CHD) is the most common 
form of congenital malformations, affecting 0.8% of live births.21 Other 
than infection, more children die from CHD in infancy than from all 
other forms of disease.25 In addition, it is estimated that at least 10% 
of early miscarriages are a consequence of severe cardiac 
malformations.10 The causes of congenital cardiac malformations are 
largely unknown. It is estimated that 18% are due to chromosomal 
causes or genetic structural abnormalities including trisomies (Trisomy 
21, 13, and 18) as well as deletion syndromes; all of these are 
associated with significant disease risk for CHD.36 A small percentage 
of congenital cardiac malformations are disorders in which underlying 
single genes have been discovered such as TBX5 in Holt-Oram 
syndrome; JAG1 in Alagille syndrome; and PTPN11, SOS1, and KRAS 
in Noonan syndrome.36 Known environmental risk factors during 
pregnancy, such as maternal diabetes or prenatal exposure to drugs, 
viruses, and reduced folate intake account for a small percentage of 
CHD cases.16,24 Although our understanding of molecular pathways in 
cardiac development has grown tremendously in the past few years, 
the etiology of human and clinically relevant CHD in the majority 
(∼75%) of cases cannot yet be identified or explained.14,16 
The widespread use of microarray-based genomic technologies 
over the past 5–6 yr have implicated copy number variants (CNVs) in 
numerous disorders such as neuropsychiatric diseases,49 craniofacial 
phenotypes, cancer, and congenital anomalies including CHD.7,18,35,36 
Relative to sequence variations such as single base-pair mutations or 
single nucleotide polymorphisms (SNPs), rare and large CNVs are 
hypothesized to confer higher disease risk as entire genes are deleted 
or duplicated.12,31 However, poor reproducibility between microarray 
platforms and the lack of standardized analytical tools highlight the 
importance of careful filtering in CNV detection studies.37 Nondisease-
related copy number polymorphisms (CNPs and/or common CNVs 
≥1%) are abundant, as evidenced by the growing Database of 
Genomic Variants (DGV).22,57 Similar to the challenges in the sequence 
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analysis of unique genetic variants, the discovery of rare etiologic 
CNVs remains a challenge, both because it is more difficult to detect a 
rare event over another event seen many times and because of the 
intrinsic low prior probability of there being such a variant at any 
particular location in the genome in any individual.28 
Recently, an algorithm to clinically interpret CNVs in patients 
with CHD was described.6 This approach is primarily based on gene 
content and overlap with known causal CHD syndromes, rather than 
on CNV inheritance and size.6 We employed a parallel approach in this 
study and utilized a strict criteria to define “likely causal” duplications 
or deletions, in well-established human CHD risk genes. We chose 100 
CHD risk genes or regions that were supported by published 
observations in human studies as a means to identify potentially 
disease-relevant CNVs. A majority of these known CHD risk genes 
were previously described or could be identified through the CHD WIKI 
portal.1,36 In addition, genes associated with recognized causal 
chromosomal abnormalities in CHD were included, as well as recently 
identified candidate genes from association studies (see Table 1).1,42 
Table 1. Known CHD risk genes 
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NS, nonsyndromic; S, syndromic, NCBI Build 36.1/hg18. 
**Animal study. 
CHD consists of heterogenous anatomy with distinct phenotypic 
subtypes. The European Paediatric Cardiac Coding (EPCC) System17 
has been cross mapped with the Society of Thoracic Surgeons/ 
European Association of Cardiothoracic Surgery (STS/EACTS) coding 
system through the International Society for Nomenclature of 
Paediatric and Congenital Heart Disease in the creation of the 
International Pediatric and Congenital Cardiac Code (IPCCC). We 
characterized cardiac malformations by subphenotyping according to 
both the EPCC and the STS/EACTS coding systems. We compared 945 
CHD cases with a publicly available cohort of 2,026 disease-free 
primarily pediatric individuals.40 Cases and controls were genotyped on 
different platforms; therefore, a second cohort of 880 control subjects 
genotyped on the same platform and within the same facility as the 
CHD cohort was included in the analysis. 
This study represents a quantitative analysis of CNVs in a large 
population of subjects with precisely phenotyped cardiac 
malformations involving 100 candidate CHD risk genes. We 
hypothesized that large rare CNVs that were statistically enriched 
against two control cohorts would be causal. A strict algorithm was 
employed to determine if subphenotypes were enriched in gains and 
losses within 100 recognized CHD risk genes selected based on gene 
content compared with two control cohorts. Finally, a novel analytical 
approach, permitting CNV gene frequency spectra to be computed as a 
proportion of each cohort containing a gain or a loss over the above 
prespecified regions, was employed to determine phenotype-gene 
dosage relationships. 
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CHD Case Ascertainment and Confirmation 
This study was reviewed and approved in accordance to 
institutionally approved research [Institutional Review Board (IRB)] 
protocols by the Children's Hospital of Wisconsin (CHW, Milwaukee, 
WI). Subjects were consented through the Congenital Heart Disease 
Tissue Bank (CHDTB) and the Wisconsin Pediatric Cardiac Registry 
(WPCR), IRB-approved research databases housed at CHW.20,47 These 
two biobanks provide DNA samples from cases and family members, 
detailed maternal environmental exposure data, family history of CHD, 
and cardiac tissue discards. 
Inclusion criteria.  
Structural congenital cardiac abnormalities, as identified within 
the IPCCC, included abnormalities of the following: the atria and atrial 
septum; atrioventricular valves or atrioventricular septum; cardiac 
position and connections; chest wall; conduction system; coronary 
arteries, arterial duct, pericardium, or arteriovenous fistulae; great 
veins; ventricles or ventricular septum; and ventriculoarterial valves or 
great arteries. 
Exclusion criteria.  
All acquired forms of pediatric heart disease in the absence of 
CHD, and frequent nonpathologic structural variants when no other 
CHD is present, included: patent foramen ovale, patent ductus 
arteriosus (PDA) under 30 days of age, PDA in premature infants (<35 
wk gestation) and mitral valve prolapse (in the absence of at least 
mild valve insufficiency). 
Note: The presence of a known or suspected chromosomal 
abnormality or known sequence variant in a CHD risk gene did not 
preclude participation in the study. In addition, the presence or 
absence of known environmental exposures did not preclude 
participation in the study. 
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Anatomic cardiac malformations were carefully characterized by 
phenotyping and subphenotyping according to both the EPCC 2011 and 
the STS/EACTS 2011 coding systems. All phenotypes were initially 
reviewed by a coding specialist, a surgeon, and a cardiologist. All 
discrepancies were reconciled by review of source documents including 
operative notes, echocardiograms, and review of operative surgeon. 
Anatomic phenotypes and subphenotypes were reported using EPCC 
2011 terms, and final confirmatory review of all cases was performed 
by a single pediatric cardiothoracic surgeon.17 In addition, information 
regarding additional diagnosis, accompanying conditions, 
demographics, and a limited number of genetic risk factors was 
obtained through the Herma Heart Center (HHC) cardiac database at 
CHW. 
Children's Hospital of Philadelphia Control Cohort 
DNA samples analyzed in this study were obtained from the 
whole blood of healthy subjects routinely seen at primary care and 
well-child clinic practices within the Children's Hospital of Philadelphia 
(CHOP) Health Care Network. Data using hg18/March 2006/build 36.1 
genomic coordinates were downloaded from http://cnv.chop.edu/.40 
High-resolution mapping of copy number variations in 2,026 healthy 
individuals was performed using the Illumina HumanHap 550 BeadChip 
(Illumina, San Diego, CA).40 
Milwaukee Family Heart Study Control Cohort 
Control subjects were drawn from the Milwaukee Family Heart 
Study (MFHS) in accordance with Medical College of Wisconsin IRB 
protocols (MCW, Milwaukee, WI). Subjects were ascertained as a 
hospital-based cohort, referred to the catheterization laboratory for 
diagnostic coronary angiography. Inclusion criteria were the ability to 
consent and age >21 yr. The following were considered exclusion 
criteria: end-stage renal disease, current treatment for a malignancy, 
and a diagnosis of coronary artery disease or a myocardial infarction at 
age >69 yr. In addition, we excluded all participants with acute 
coronary syndrome and significant valvular disease. Individuals with a 
diagnosis of other cardiac structural abnormalities were excluded 
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based on either the result of echocardiography prior to or as 
determined during the invasive cardiac procedure. 
Genomic DNA Extraction 
Genomic DNA for CHD and MFHS cohorts was obtained from 
peripheral blood using standard protocols for DNA isolation from Roche 
Diagnostics, Promega Biotech (Wizard), and Qiagen (Gentra 
Puregene). Purified genomic DNA was resuspended in 1.0 mM Tris HCl 
pH 8.0 and 0.1 mM EDTA. DNA quality was tested by optical density 
260/280 ratios, quantified by UV spectrophotometry using a Nanodrop 
2000 (Thermo Scientific, Wilmington, DE). DNA stocks were stored at 
−80°C, dilutions for microarray analysis were stored at 100 ng/μl at 
−20°C. 
CHD Risk Gene Prioritization and Selection 
Genes or regions with previously associated disease/syndrome 
variants as identified through the CHD WIKI website (searched 
01/04/2011 and updated 07/28/2011) and/or supported by previously 
published observations in human studies were selected.1,34,36,42,48 
These known CHD risk genes are outlined in Table 1. 
Briefly, CHD WIKI offers an updated overview of genes 
implicated in human CHD, obtained by an OMIM search, and 
complemented with a study of the PubMed literature concerning 
mutation analysis of candidate genes for congenital heart defects.1 The 
level of support was defined by inheritance of the mutation (de novo 
or inherited and segregated with a phenotype) and the association of a 
variant in the investigated CHD population vs. a normal control 
population.1 A comprehensive list of 100 CHD risk genes was selected; 
the vast majority of these selected genes are known to be expressed 
in the human heart.3,11,43,46,50,54 According to CHD WIKI, syndromic 
genes were defined as congenital heart defects that are associated 
with a second major malformation (i.e., renal defects, cleft palate, 
brain malformations), with developmental delay or mental handicap, 
and/or the presence of dysmorphism. 
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Genotyping for the CHD and MFHS control cohort was performed 
with the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 
Santa Clara, CA) as previously described.30,47 All samples were run in 
the Advanced Genomics (AGEN) laboratory core at the Children's 
Research Institute (CRI)/MCW (Milwaukee, WI). A reference genomic 
DNA control sample, ref 103, supplied by Affymetrix, was run with 
every batch of subjects (Santa Clara, CA). 
CNV Analysis and Quality Control 
The CHD subject cohort comprised 1,020 subjects consented through 
the CHDTB or WPCR. We evaluated the quality and suitability of the 
subject population for a genetic association study. The population was 
required to pass copy number analysis quality metrics as seen in Table 
2. 
Table 2. Quality control of CHD case and MFHS control cohorts and 
genotyping data 
 Subjects, n  Subjects, n 
MFHS Control Cohort  CHD Case Cohort  
    Starting subjects 950     Starting subjects 1,020 
    Remaining subjects 880     Remaining subjects 958 
QC Exclusions % Total  % Total 
    MAPD QC 3.05 MAPD QC 2.35 
    Segment QC 4.32     Segment QC 2.15 
    Consent QC NA     Consent QC 0.10 
    Sex QC NA     Sex QC 0.59 
Copy number analysis exclusions were as follows: median absolute pairwise difference 
(MAPD) quality control (QC) ≥0.35, number of copy number polymorphism (CNP) 
segments ≥250, 1 subject with a status change to his/her consent, and sex tracking 
QC. Congenital heart disease (CHD) cases were reduced to a final n = 945 after 
inclusion and exclusion criteria were met. 
CNV identification of study subjects required the processing of 
Affymetrix intensity (CEL) files using Genotyping Console version 3.0.2 
(GTC) software as previously described.20,47 CEL files of subjects with a 
median absolute pairwise difference >0.35 and a CNV segmentation 
count ≥250, indicative of poor DNA quality, were excluded from the 
study. 
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A final number of 945 CHD subjects and 880 MFHS controls 
remained in the study after inclusion and exclusion criteria were met. 
As summarized in Table 3, the cases and controls were stratified 
according to age, sex, and race/ethnicity. 
Table 3. CHD case, CHOP, and MFHS control cohort demographics 






Race    
    Caucasian 655 1,320 870 
    African 
American 
92 694 5 
    Native 
American 
14  5 
    Hispanic 90   
    Asian 26 12  
    Other 68   
Total 945 2,026 880 
Sex, %    
    Female 44.02  36.59 
    Male 55.87  63.41 
Age, yr    
    Median age 0.62  67.00 
    Average age 4.03  65.66 
CHOP, Children's Hospital of Philadelphia ; MFHS, Milwaukee Family Heart Study. 
Copy number state of those subjects who passed quality control 
thresholds were determined with reference to the 
GenomeWideSNP_6.hapmap270 file and copy number calls were 
determined using the Affymetrix GTC segmentation algorithm. To 
reduce the presence of false positive CNVs, the segmentation 
algorithm parameters were set to identify only those regions larger 
than 25 kb comprising at least 25 contiguous markers. It has been 
shown that CNVs smaller than this are frequently false positive 
detection.40 In addition, all segments were monitored for degree of 
overlap with previously identified common CNVs, annotated by the 
DGV.22,57 
Using a BED file format (chromosome, gene starting position, 
gene ending position, gene name), copy number information was 
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drawn from custom gene regions (Table 1) extracted from the 
processed segment data. 
A flowchart for copy number analysis is presented in Fig. 1. A 
multipurpose Access database (Microsoft, Redmond, WA) served as a 
central repository for the cohort demographic data as well as the 
entire experimental set of copy number variant data. Database tables 
were populated with copy number data from the GTC analysis, detailed 
demographic data, and the annotated 100 CHD risk gene list (Table 1). 
Demographic data for CHD cases and MFHS controls were obtained via 
clinical and consent verification methods. SQL query results included 
aggregate CNV counts by phenotype or region for both CHD and MFHS 
controls. Graphical representation of the query results was 
accomplished using Excel (Microsoft) and R.45 Supplemental Table S1 
includes a complete summary of all CNV profiles over the 100 CHD risk 
gene list for each subject as well as phenotypic and demographic 
information.1 
 
Fig. 1. CNV analysis flowchart from sample to statistics. Blue figures represent 
software used or a process/task performed. Red figures represent data files. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
17 
 
Overall CNV burden.  
The total number of large CNVs throughout the genome was 
calculated by importing GTC segment files filtered by size (duplication 
≥200 kb or deletion ≥100 kb) into an Access database. An external R 
program further filtered CNVs for all Build 36 annotated genes that did 
not occur as a CNP, defined as a normal variant (≥1%) in either the 
CHOP or MFHS control cohorts. 
Algorithm for likely causal CNV determination.  
A strict algorithm was employed to determine likely causal 
CNVs. Gains and losses were considered as potentially disease relevant 
if they fulfilled the following criteria: 1) size: duplication ≥200 kb or 
deletion ≥100 kb, 2) they did not occur as a CNP, defined as a normal 
variant (≥1%) in either CHOP or MHFS control cohort, and 3) CNV 
occurred over a gene region known to be associated with CHD (CHD 
100 gene list). 
A final step was taken because the MFHS cohort was aged and 
significantly different from CHD cases. Sex chromosome degradation in 
peripheral blood appears to be an age-related phenomenon.19 Studies 
have shown that a strong correlation exists between patient age and 
loss of the Y chromosome.52 Sex chromosome degradation is easily 
detected by the segment reports created by GTC because males have 
only one copy of Chr. X. To optimize the analysis of sex chromosomes, 
sex-matched references were employed; for X chromosome analysis, 
only females from all three cohorts were compared.55 Thus male MFHS 
controls were excluded from X chromosome results in all CNV 
analyses. 
CNV frequency by phenotype.  
CNVs fulfilling criteria 1–3 were analyzed for enrichment by 
subphenotypes. 
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CNV frequency by gene region.  
CNV frequency “spectra” were computed as a proportion of each 
cohort containing a gain or a loss over the CHD associated gene list. 
Complex CNV analysis.  
To determine if subjects carried multiple CNVs, large rare CNVs 
outside of and in addition to the defined set of 100 disease-related 
CHD genes were screened using criteria 1 and 2 (see Ref. 56). 
Confirmatory Studies 
CNVs that were identified in the CHD cases were confirmed by 
either karyotype, FISH analysis, or TaqMan CN real-time quantitative 
PCR assays (Applied Biosystems). CNVs for one case asterisked in 
Table 5 was difficult to confirm and is currently pending, due to 
inconclusive TaqMAN copy number results. A representative set of 
identified CNVs within the CHOP cohort were previously validated,40 
whereas CNVs identified in the MFHS cohort as part of this study were 
not confirmed. As a means of secondary CNV confirmation of CHD 
cases, microarray analysis was performed by an independent lab on a 
number of the CHD study subjects (n = 34). TaqMan copy number 
reactions (Table 1) were run in triplicate on an ABI HT7900 instrument 
(Applied Biosystems) under the following cycling conditions: 50°C for 2 
min, 95°C for 10 min, then 40 cycles of 95°C for 15 s followed by 
60°C for 1 min. Typically ∼20 ng of template genomic DNA was 
amplified in reaction volumes of 10 μl, as previously described.47 Copy 
number confirmations were assessed using a calibrator panel of six 
individuals with known copy number state over the gene of interest 
and analyzed using Copy Caller software version 1.0 (Applied 
Biosystems). If parents of subjects with confirmed CNVs were 
available, their DNA was analyzed to determine if CNVs were inherited 
or de novo, as noted in Table 5. 
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Table 5. Case reports of likely causal CNVs 





































2 AS (valvar) CHD1L 
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5q35.3 




































3 AS (valvar) FOXC1 all Loss 6p25.3–
6p25.2 
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26 TOF HOXA1 all Gain 7p15.2–
7p15.1 
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29 TRI-AT MAPK1 all Gain 22q11.21–
22q11.22 











30 TRI-AT NSD1 e24-3′ 
UTR 


















31 Truncus arteriosus MAPK1 all Loss 22q11.21–
22q11.22 
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*Inconclusive TAQMAN results (see Subject 28). Boldface indicates confirmed genes. 
“Unknown” means one parental DNA was unavailable. “Other cardiac” phenotype (case 
19) is double-chamber right ventricle (DCRV). 
Statistical Analysis 
Since the expected incidence is very small (typically <5%) tests 
based on a normality assumption would be incorrect, therefore a one-
tailed Barnard exact test was used for all comparisons of proportions 
of CNVs.8 A P ≤ 0.05 without adjustment is used for significance. A 
custom R program was used to calculate the P value and checked 
using Cytel StatXact (Cytel, Cambridge, MA).15 StatXact was also used 
to calculate power. With a sample of 810, and a CNV incidence of 
4.3%, we would have at least 90% power to detect a significant 
difference from 0.0196 (the CNV incidence of CHOP cohort's 
39/2,026). We have given other power calculations for possible 
scenarios of subphenotypes (Fig. 2). We see that in an n = 100 sample 
group we would have ≥80% power if we had an 8% CNV incidence. 
For a cohort of 200 we would have ≥80% power to detect a difference 
of 6% CNV incidence. 
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Fig. 2. Sample size (n) and copy number variant (CNV) proportion (fraction), required 
to detect difference from 0.0196 (CHOP control CNV fraction) at an alpha = 0.05, 
power at least 80%. CHOP, Children's Hospital of Philadelphia. 
This figure demonstrates the sample size required (x-axis) with 
power of at least 80% under varying CNV proportions (y-axis) when 
the control cohort is 0.0196 (CHOP control CNV proportion) at an 
alpha = 0.05. 
Results 
Phenotypes of CHD Study Subjects 
Subjects diagnosed with congenital heart malformations (n = 
945) and phenotyped in accordance with the EPCC terms were 
categorized into the 40 cardiac subphenotypes listed in Table 4 (17). 
The five largest phenotypes represented were as follows: hypoplastic 
left heart syndrome (HLHS) 14.8%, ventricular septal defect (VSD 
perimembranous) 7.7%, tetralogy of Fallot (TOF) 7.7%, coarctation of 
the aorta (CoA) 7.0%, and atrioventricular canal complete (AVC 
complete) 5.0%. The majority of subjects were represented by 
individual subphenotypes most of which contained <5.1% of the total 
CHD cohort. 
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Table 4. CHD cohort by subphenotypes 
Diagnoses Subjects % of 
Total 
Diagnoses Subjects % of 
Total 
Aorto-pulmonary window + 
Patent Ductus Arteriosus 
(PDA)T21 
5 0.53 Mitral Valve Stenosis (MS, 
subvalvar, parachute)22q 
6 0.63 
AVSD + TOF (AVSD + TOF)T21 7 0.74 Other, CardiacT21, 22q 18 1.90 
Arrhythmias (Congenital 
Heart Block, Long QT, WPW) 
7 0.74 Pulmonary Atresia (PA) 
  
Aortic Stenosis (Valvar)T 31 3.28 - IVS-T21 18 1.90 
Atrial Septal Defect 
Secundum (ASD-SEC)T21 
47 4.97 - VSD-22q 34 3.60 
Atrial Septal Defect Sinus 
Venosus (ASD-SV) 
13 1.38 PAPVR 12 1.27 
A-V Canal Complete (AVC 
Complete)T21 
48 5.08 Pulmonary Stenosis (Valvar) 9 0.95 
A-V Canal Intermediate (AVC 
Intermediate)T21 
7 0.74 Shone's 8 0.85 
A-V Canal Partial (AVC 
Partial)T21 
17 1.80 Subaortic stenosisT21 12 1.27 
A-V Canal Unbalanced + 
AVSD with ventricular 
imbalanceT21 
14 1.48 Supravalvar aortic stenosis 
(supravalvar AS) 
4 0.42 





4 0.42 Tetralogy of Fallot (TOF)T21, 
22q 
73 7.72 
Chest Wall 4 0.42 Transposition of Great 
Arteries (TGA) 
  
Coarctation of the Aorta 
(CoA)T 
66 6.98 - IVS - 21 2.22 
Coronary Arteries (COR ART) 10 1.06 - VSD - 21 2.22 
Double Inlet Left Ventricle 
(DILV) 
19 2.01 Tricuspid Atresia (TRI-AT) 29 3.07 
Double Outlet Right Ventricle 
(DORV)22q 
41 4.34 Truncus Arteriosus (TA)22q 29 3.07 
Ebstein's Anomaly 
(EBSTEINS) 
9 0.95 Vascular ring and PA slingT21, 
22q 
14 1.48 
Hypoplastic Left Heart 
Syndrome (HLHS)T 
140 14.81 VSD inletT21 4 0.42 
Interrupted Aortic Arch 
(IAA)22q 
11 1.16 VSD multiple + muscular 10 1.06 
L-TGA 7 0.74 VSD perimembranousT21, 22q 73 7.72 
Dilated Ascending Aorta 
(MARFAN) 
8 0.85 VSD subarterialT21 7 0.74 
The following individual phenotypes were included in the “other cardiac” subphenotype 
category: single ventricle other, absent left pulmonary artery (LPA), absent pulmonary 
valve, aorto-left ventricular tunnel, bicuspid aortic valve (BAV), cor triatriatum, 
double-chamber right ventricle (DCRV), left ventricular aneurysm, tricuspid 
regurgitation, true cleft of mitral leaflet (without AVSD). Superscripts were used to 
denote phenotypes where causal chromosomal as shown abnormalities were observed 
(see results, where T21 = Trisomy 21, 22q = 22qDS, and T = Turner's Syndrome). 
PAPVR, partial anomalous pulmonary venous return; VSD, ventricular septal defect. 
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Subjects With Recognized Causal Chromosomal 
Abnormalities 
We ascribed 135 subjects to known CHD-related chromosomal 
abnormalities [T21 (n = 80), T18 (n = 1), 22qDS (n = 42), Turner (n 
= 8), William's (n = 3), and XXX (n = 1)].36,44 The syndromes and 
their associated phenotypes were as follows: T21: aorto-pulmonary 
window with PDA n = 2; AVSD + TOF n = 5; ASD-SEC n = 4; AVC 
complete n = 35; AVC intermediate n = 5; AVC partial n = 2; AVC 
unbalanced + AVSD with ventricular imbalance n = 1; other cardiac n 
= 1; pulmonary atresia (PA), IVS n = 1; subaortic stenosis n = 1; TOF 
n = 6; vascular ring + PA sling n = 1; VSD (inlet) n = 2; VSD 
(perimembranous) n = 13 and VSD (subarterial) n = 1, T18: TOF n = 
1, 22qDS: DORV n = 1; IAA n = 4; mitral stenosis, subvalvar, 
parachute + mitral stenosis n = 1; other cardiac n = 1; PA, VSD n = 
10; TOF n = 9; truncus arteriosus n = 12; vascular ring + PA sling n = 
1 and VSD (perimembranous) n = 3, Turner: aortic stenosis (valvar) n 
= 1; CoA n = 4 and HLHS n = 2, mosaic Turner: CoA n = 1, William's: 
supravalvar aortic stenosis and XXX: PA, IVS. 
Overall CNV Burden 
The total number of large CNVs (≥100 kb loss, ≥200 kb gain) 
throughout the genome were similar in both CHD and MFHS cohorts. 
When subjects with chromosomal abnormalities such as Trisomy 21 
and 18, Turner, 22qDS, William's, and XXX were excluded, a 
significant number of the CHD cohort, 567 out of 810, carried a large 
rare CNV over a gene somewhere in their genome, while in the MFHS 
control cohort, this number was 391 of 880. Gains were twofold more 
common than losses in both cohorts despite the requirement to be 
twice as long (Fig. 3). 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 




Fig. 3. Total CNV burden by cohort. Standard box-and-whiskers plot for the 
distribution of large rare CNV segment count per subject in each of 4 cases: congenital 
heart disease (CHD) vs. Milwaukee Family Heart Study (MFHS) and gains vs. losses. 
Boxes represent the 1st and 3rd quartiles of each distribution, thick horizontal lines 
represent the median value, circles represent outliers, or the CHD cohort, major 
syndromes would significantly skew the distribution, so those subjects were excluded, 
leaving 810 syndrome-free subjects. Trisomy 21 and 18, Turner, 22qDS, William's and 
XXX chromosomal abnormalities were therefore excluded. 
CHD Case Reports 
Likely etiologic large, rare CNVs were identified in 35 CHD 
subjects. Table 5 summarizes the complete list of CHD subjects with 
CNVs over the known CHD risk gene regions (excluding the 135 
subjects with known CHD-related chromosomal abnormalities). Three 
HLHS subjects (cases 16, 17, and 18) were studied for inheritance, a 
gain over FKBP6 was found to be a de novo event, a gain involving 
GATA4 and SOX7 was not present in one parent and the status of the 
other parent was unknown, and the MYH11 gain was inherited. Table 5 
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reports all of the known genes within each CNV segment, including our 
selected 100 CHD-associated genes. 
Statistical Analysis of CNVs 
Subphenotype analysis.  
The CHD cohort, even after excluding genes involved in the 
known CHD-related chromosomal abnormalities, was enriched in large, 
rare CNVs involving CHD risk genes, where 35 of 810 subjects carried 
such a CNV (P ≤ 0.05 vs. both CHOP with 39 of 2,026 and MFHS with 
14 of 880). Breaking this cohort into subgroups by specific phenotype 
often resulted in groups too small for statistical significance. Different 
subdivision schemes may achieve nominal significance. The entries in 
Table 6 where the frequency of CNV was significantly (P ≤ 0.05) 
different from the CHOP and MFHS cohorts are marked with a double 
asterisk. The CHD cohort, after excluding known causal chromosomal 
abnormalities, showed a frequency of CNV at 4.3%, and a power 
calculation is performed in Fig. 2 showing the difficulty in detecting a 
difference from the control's 1.9%. For subgroups of 10–25 
individuals, the power to detect a difference from 1.9% (CHOP) 
required a proportion of 30 and 17%, respectively. Phenotypes 
showing significant (P ≤ 0.05) enrichment of large CNV events were 
aortic stenosis (valvar), AV canal (partial), AVSD with TOF, subaortic 
stenosis, TOF, and truncus arteriosus. Although HLHS was the most 
common phenotype in the CHD case cohort, this phenotype did not 
demonstrate significant large rare CNV enrichment. 
Table 6. CNV frequency by subphenotype 
 
Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 


























CHOP Cohort 2,026 19 (0.94) 20 (0.99) 39 (1.92) 2,026 19 (0.94) 20 (0.99) 39 (1.92) 
MFHS Cohort 880 3 (0.34) 11 (1.25) 14 (1.59) 880 3 (0.34) 11 (1.25) 14 (1.59) 




810 12 (1.48) 23 (2.84) 35 
(4.32)** 
    Turner 8 8 (0.84) 1 (0.10) 8 
    
    Trisomy18 (T18) 1 0 (0.00) 1 (0.10) 1 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 


























    Trisomy21 (T21) 80 0 (0.00) 80 (8.35) 80 
    
    Williams 3 3 (0.31) 0 (0.00) 3 
    
    XXX 1 0 (0.00) 1 (0.10) 1 
    
    22qDS 42 42 (4.38) 1 (0.10) 42 
    
Aorto-pulmonary window + PDA 5 0 (0.00) 2 (40.00) 2 
(40.00)** 
3 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 2 
  
2 2 
   
    22qDS 0 
   
0 
   
AVSD + TOF (AVSD + TOF) 7 0 (0.00) 6 (85.71) 6 
(85.71)** 
2 0 (0.00) 1 (50.00) 1 
(50.00)** 
    Trisomy21 5 
 
5 5 
    
    22qDS 0 
  
0 
    
Aortic Stenosis (Valvar) 31 3 (9.68) 1 (3.23) 4 
(12.90)** 
30 2 (6.67) 1 (3.33) 3 
(10.00)** 
    Turner 1 1 
 
1 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Atrial Septal Defect Secundum 
(ASD-SEC) 
47 1 (2.13) 4 (8.51) 5 
(10.64)** 
43 1 (2.33) 0 (0.00) 1 (2.33) 
    Trisomy21 4 
 
4 4 
    
    22qDS 0 
  
0 
    
Atrial Septal Defect Sinus 
Venosus (ASD-SV) 
13 1 (7.69) 0 (0.00) 1 (7.69) 13 1 (7.69) 0 (0.00) 1 (7.69) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
A-V Canal Complete (AVC 
Complete) 




13 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 35 
 
35 35 
    
    22qDS 0 
  
0 
    
A-V Canal Intermediate (AVC     
Intermediate) 
7 0 (0.00) 5 (71.43) 5 
(71.43)** 
2 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 5 
 
5 5 
    
    22qDS 0 
  
0 
    
A-V Canal Partial (AVC Partial) 17 1 (5.88) 3 (17.65) 4 
(23.53)** 
15 1 (6.67) 1 (6.67) 2 
(13.33)** 
    Trisomy21 2 
 
2 2 
    
    22qDS 0 
  
0 
    
A-V Canal Unbalanced + AVSD 
with ventricular imbalance 
14 0 (0.00) 2 (14.29) 2 
(14.29)** 
13 0 (0.00) 1 (7.69) 1 (7.69) 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
Coarctation of the Aorta (CoA) 66 6 (9.09) 2 (3.03) 8 
(12.12)** 
61 1 (1.64) 1 (1.64) 2 (3.28) 
    Turner 5 5 1 5 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 


























Double Inlet Left Ventricle (DILV) 19 0 (0.00) 1 (5.26) 1 (5.26) 19 0 (0.00) 1 (5.26) 1 (5.26) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Double Outlet Right Ventricle 
(DORV) 
42 1 (2.38) 3 (7.14) 4 
(9.52)** 
41 0 (0.00) 2 (4.88) 2 (4.88) 
    Trisomy21 0 
  
0 
    
    22qDS 1 1 1 1 
    
Ebstein's Anomaly (EBSTEINS) 9 0 (0.00) 1 (11.11) 1 (11.11) 9 0 (0.00) 1 (11.11) 1 (11.11) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Hypoplastic Left Heart Syndrome 
(HLHS) 
140 2 (1.43) 5 (3.57) 7 
(5.00)** 
138 0 (0.00) 4 (2.90) 4 (2.90) 
    Turner 2 2 
 
2 
    
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Interrupted Aortic Arch (IAA) 11 4 (36.36) 0 (0.00) 4 
(36.36)** 
7 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    22qDS 4 4 
 
4 
    
Mitral Valve Stenosis (MS, 
subvalvar, parachute) 
6 1 (16.67) 0 (0.00) 1 (16.67) 5 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    22qDS 1 1 
 
1 
    
Other, Cardiac 18 1 (5.56) 2 (11.11) 3 
(16.67)** 
16 0 (0.00) 1 (6.25) 1 (6.25) 
    Trisomy21 1 
 
1 1 
    
    22qDS 1 1 
 
1 
    
Pulmonary Atresia (PA) 
    
16 0 (0.00) 0 (0.00) 0 (0.00) 
-IVS- 18 0 (0.00) 2 (11.11) 2 
(11.11)** 
    
    Trisomy21 1 
 
1 1 
    
    XXX 1 
 
1 1 
    
    22qDS 0 
  
0 
    
-VSD- 34 10 
(29.41) 
1 (2.94) 11 
(32.35)** 
24 0 (0.00) 1 (4.17) 1 (4.17) 
    Trisomy21 0 
  
0 
    
    22qDS 10 10 
 
10 
    
Subaortic stenosis 12 0 (0.00) 3 (25.00) 3 
(25.00)** 
11 0 (0.00) 2 (18.18) 2 
(18.18)** 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
Supravalvar AS 4 3 (75.00) 0 (0.00) 3 
(75.00)** 
1 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 0 
  
0 
    
    Williams 3 3 
 
3 
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Totals Including Causal 
Chromosomal Abnormalities 
 
Totals Excluding Causal 
Chromosomal Abnormalities 
 


























    22qDS 0 
  
0 
    






57 2 (3.51) 3 (5.26) 5 
(8.77)** 
    Trisomy18 1 
 
1 1 
    
    Trisomy21 6 
 
6 6 
    
    22qDS 9 9 
 
9 
    
Tricuspid Atresia (TRI-AT) 29 0 (0.00) 2 (6.90) 2 (6.90) 29 0 (0.00) 2 (6.90) 2 (6.90) 
    Trisomy21 0 
  
0 
    
    22qDS 0 
  
0 
    
Truncus Arteriosus (TA) 29 14 
(48.28) 
1 (3.45) 14 
(48.28)** 
17 2 (11.76) 1 (5.88) 2 
(11.76)** 
    Trisomy21 0 
  
0 
    
    22qDS 12 12 
 
12 
    
Vascular ring and PA sling 14 1 (7.14) 1 (7.14) 2 
(14.29)** 
12 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 1 
 
1 1 
    
    22qDS 1 1 
 
1 
    
VSD inlet 4 0 (0.00) 2 (50.00) 2 
(50.00)** 
2 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 2 
 
2 2 
    
    22qDS 0 
  
0 
    
Ventricular Septal Defect (VSD 
perimembranous) 




57 2 (3.51) 2 3 (5.26) 
    Trisomy21 13 
 
13 13 
    
    22qDS 3 3 
 
3 
    
Ventricular Septal Defect (VSD 
subarterial) 
7 0 (0.00) 1 (14.29) 1 (14.29) 6 0 (0.00) 0 (0.00) 0 (0.00) 
    Trisomy21 1 
 
1 1 
    
    22qDS 0 
  
0 
    
**Significance over both CHOP and MFHS controls (P ≤ 0.05). Four patients had both 
gains and losses but are only counted once in the column “Subjects with CNV Loss or 
Gain”. The following subphenotypes contained 0 subjects with a CNV and were 
therefore removed from the table: Arrhythmias (Congenital Heart Block, Long QT, 
WPW), 7; Cardiomyopathy (DILATED), 13; Cardiomyopathy (HYPERTROPHIC), 4; 
Chest Wall, 4; Coronary Arteries (COR ART), 10; L-TGA, 7; Dilated Ascending Aorta 
(MARFAN), 8; Partial Anomalous Pulmonary Venous Return (PAPVR), 12; Pulmonary 
Stenosis (Valvar), 9; Shone's, 8; Total Anamolous Pulmonary Venous Connection 
(TAPVC; infracardiac, intracardiac, mixed, supracardiac), 15; Transposition of Great 
Arteries (IVS), 21; (VSD), 20; and Ventricular Septal Defect (VSD multiple + 
muscular), 10 (n = 161 total). 
CNV gene frequency analysis and gene enrichment.  
In addition, CNV frequency “spectra” were computed as a 
proportion of each cohort containing a gain or a loss over 100 CHD 
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genes of interest (Fig. 4). (Spectra for individual CHD subphenotypes 
with statistically higher CNV frequencies are represented in Fig. 5.) 
The frequency of genes with gain or loss was compared with both 
control cohorts and significantly enriched genes are listed in Table 7. 
In addition, Supplemental Table S1 includes a complete summary of all 
CNV profiles over the 100 CHD risk gene list for each CHD subject, and 
a heatmap (Supplemental Fig. S1) illustrates the clustering of various 
groups of multiple subjects who share contiguous blocks of deleted or 
duplicated genes. 
 
Fig. 4. CNV frequency spectrum. Note that any gene showing 0% CNV frequency in all 
3 cohorts was omitted from this figure due to space considerations. Vertical error bars 
drawn represent 1 SD from the mean in the estimated sampling distribution. From this 
visualization it is clear that gains over gene FKBP6 on chromosome 7 occur in all 3 
cohorts, while losses of the same gene are only seen in the CHD cohort, implying a 
loss could cause CHD. 
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Fig. 5. CNV frequency spectra of significantly enriched phenotypes. Note that any 
gene showing 0% CNV frequency in all 3 cohorts was omitted from this figure due to 
space considerations. Vertical error bars drawn represent 1 SD in the estimated 
sampling distribution. Significantly enriched phenotypes included: aortic stenosis 
(valvar), atrioventricular canal (partial), atrioventricular septal defect (AVSD) with 
tetralogy of Fallot (TOF), subaortic stenosis, TOF, and truncus arteriosus. 
 
Table 7. CHD-associated gene regions significantly enriched with large, rare 
CNVs 






Gene CHD CHOP MFHS CHD CHOP MFHS Gains Losses 
PRKAB2 0.4 0.1 0.0 0.2 0.1 0.2 √  
FMO5 0.4 0.1 0.0 0.2 0.1 0.2 √  
CHD1L 0.4 0.1 0.0 0.2 0.1 0.2 √  
BCL9 0.3 0.1 0.0 0.2 0.1 0.2 √  
ACP6 0.3 0.1 0.0 0.2 0.1 0.2 √  
GJA5 0.3 0.1 0.0 0.2 0.1 0.2 √  
FKBP6 0.3 0.1 0.3 0.3 0.0 0.0  √ 
ELN 0.0 0.0 0.0 0.3 0.0 0.0  √ 
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Gene CHD CHOP MFHS CHD CHOP MFHS Gains Losses 
GTF2IRD1 0.0 0.0 0.0 0.3 0.0 0.0  √ 
GATA4 0.1 0.0 0.0 0.3 0.0 0.0  √ 
HRAS 0.3 0.0 0.0 0.0 0.1 0.0 √  
GATA6 0.3 0.0 0.0 0.0 0.0 0.0 √  
RUNX1 8.5 0.0 0.0 0.0 0.0 0.0 √  
CRKL 0.4 0.0 0.3 4.2 0.1 0.0  √ 
TBX1 0.2 0.0 0.2 4.4 0.1 0.0  √ 
ATRX 0.2 0.0 0.0 1.9 0.0 0.0  √ 
GPC3 0.2 0.0 0.0 1.9 0.0 0.0  √ 
BCOR 0.2 0.0 0.0 1.9 0.0 0.3  √ 
ZIC3 0.2 0.1 0.0 1.9 0.0 0.0  √ 
FLNA 0.2 0.1 0.0 1.9 0.0 0.0  √ 
MID1 0.2 0.0 0.3 2.1 0.0 0.3  √ 
The statistical test applied was the Barnard's exact test. Of our 100 candidate genes, 
21 were found to be significantly enriched for CNVs (null hypothesis rejected P ≤ 0.05 
in both cohorts: CHD vs. CHOP and CHD vs. MFHS, see boldface). We used the full 
cohorts for genes in autosomal chromosomes, and only the female portion for any 
genes on chromosomes (Chr.) X or Y. This leaves 322/880 for MFHS, 416/945 for 
CHD, and an estimated 1,013/2,026 for CHOP, usable for testing on the Chr. X genes. 
Numerous genes were identified as significantly enriched (P ≤ 
0.05 against both control cohorts), including losses, FKBP6, ELN, 
GTF2IRD1, GATA4, CRKL, TBX1, ATRX, GPC3, BCOR, ZIC3, FLNA and 
MID1, and gains, PRKAB2, FMO5, CHD1L, BCL9, ACP6, GJA5, HRAS, 
GATA6, and RUNX1. These genes are identified in Table 7. 
The authors recognize that syndromic forms of congenital heart 
disease are relatively well understood; therefore, genes in 
chromosomal abnormalities known to be causally related to CHD were 
intentionally kept on the 100 candidate CHD risk gene list to contrast 
with CNVs found elsewhere. For instance, haploinsufficiency of the 
genes associated with William's Syndrome, FKBP6, ELN, and 
GTF2IRD1, identified the three William's Syndrome patients in the 
study.1 Losses of the TBX1 and CRKL genes are associated with 22qDS 
and were observed in deleted subjects.32,53 Turner syndrome subjects 
carrying losses on the chromosome X genes involving MID1, BCOR, 
ATRX, GPC3, ZIC3, and FLNA were identified, as well as a female 
subject (XXX) who was identified with gains over these chromosome X 
gene regions. In addition, duplications involving RUNX1 were primarily 
Trisomy 21 subjects. 
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Gains at 1q21.1 including PRKAB2, FMO5, CHD1L, BCL9, ACP6, 
and GJA5 were significantly enriched in this study; however, losses 
that were observed in both control cohorts as well as the CHD cohort 
were not. Interestingly, gains at 1q21.1 were previously reported in 
isolated sporadic TOF.18 In our case cohort we observed one subject 
(case 24) with TOF (2 contiguous CNVs, 0.6 and 1.6 Mb), one subject 
(case 20) with PA-VSD (1.5 Mb), and another (case 10) with CoA (1.5 
Mb). One complex subject (case 2) with AS valvar and Shone's had a 
shorter gain (418 kb) involving only PRKAB2, FMO5, and CHD1L in 
conjunction with a 1.8 Mb gain at 5q35.2, which included the NSD1 
gene. 
Chromosome 8p23.1 deletions involving GATA4 were enriched 
and have been reported as a cause of complex congenital heart 
defects and diaphragmatic hernia.51 These included subjects with AVC 
partial (case 6, 3.8 Mb loss), VSD perimembranous (case 34, 4.5 Mb 
loss), and ASD-SV (case 5, 304 kb loss). 
Three subjects had gains involving the HRAS gene. The first was 
found in a complex subject with coarctation of the aorta: in addition to 
a 284 kb duplication involving the HRAS gene the subject had Turner 
syndrome. The remaining two gains (case 12, 256 kb; case 22, 271 
kb) were found in subjects with DILV and subaortic stenosis, 
respectively (Table 5). Cardiovascular malformations are known to be 
related to Ras/MAPK pathway syndromes, and previous literature 
findings have reported associations of HRAS mutations in Costello 
Syndrome and with the subaortic stenosis phenotype.29 These gains 
involving HRAS appear to expand phenotypes related to the Ras/MAPK 
pathway. 
Enriched CNVs identified in Table 7 are previously reported or 
can be found in the Database of Chromosomal Imbalance and 
Phenotype in Humans Using Ensembl Resources (DECIPHER) with the 
exception of the gains involving GATA6. One of the three gains 
involving GATA6 was in a subject with Trisomy 18 with TOF. The 
remaining two subjects with CNV gains involving GATA6 were 1) a 
subject (case 31) with truncus arteriosus with a complex CNV over two 
CHD genes of interest, a 308 kb gain including GATA6, and a 1.2 Mb 
22q11.2 distal deletion involving MAPK1 (losses in the distal region of 
22q11.2 have previously been reported in subjects with truncus 
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arteriosus),2 and 2) a subject (case 35) with VSD perimembranous 
with two neighboring 6.1 and 6.9 Mb gains involving a gain on GATA6. 
Although sequence variants in GATA6 have been previously found to 
be associated with cardiac outflow tract defects,27 these gains have not 
been reported and suggest possible GATA6 triple sensitivity to 
conotruncal defects. 
Collapsing groups of phenotypes by recognized causal 
chromosomal abnormalities.  
To increase statistical power, a strategy for summing cohorts 
was employed; subphenotypes associated with T21, 22qDS, and 
Turner Syndrome (see Tables 4 and 6) were collapsed into three 
groups, respectively.33 We hypothesized collapsing subphenotypes into 
genetically related groups would increase power to detect additional 
related CNVs by phenotype. The three collapsed groups each 
demonstrated significant enrichment (P ≤ 0.05) of additional CNVs 
compared with both control cohorts (see Table 8 - Enriched Syndrome 
Genes and Fig. 6 - Spectra). Large, rare CNVs were significantly more 
frequent (P ≤ 0.05) in the groups of T21 subphenotypes and included 
gains involving GATA6 and RUNX1 and losses involving GATA4, SOX7, 
TBX1, and CRKL. Likewise, collapsing the HLHS, CoA, and AS (valvar) 
subphenotypes, which made up the Turner syndrome group, indicated 
significant gains involving the 1q21.1 gene regions, enriched losses 
involving the Chr. X genes, as well as gains involving GATA4, SOX7, 
EHMT1 (case 15), and HRAS and losses involving FOXC1 (case 3) and 
NOTCH1 (case 11). Although the T21 and 22qDS subclasses share 
some overlap of phenotypes (other cardiac, TOF, vascular ring/PA 
sling, and VSD perimembranous), it is interesting to note that the 
22qDS grouping also included gains involving the 1q21.1 genes as well 
as GATA6 and RUNX1. Significant CNV losses within the 22qDS 
subclasses involved TBX1 and CRKL. All CNVs identified through the 
collapsed phenotypes are listed in Table 8 and are reported in 
DECIPHER. 
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Boldface indicates significant values. 
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Fig. 6. CNV frequency spectra of collapsed phenotypes by syndrome. Note that any 
gene showing 0% CNV frequency in all 3 cohorts was omitted from this figure due to 
space considerations. Vertical error bars drawn represent 1 SD in the estimated 
sampling distribution. Turner phenotypes, T21 phenotypes, and 22qDS phenotypes. 
Additional findings of note include a gain involving TBX20 and 
loss involving SALL4. Three losses including TBX20 have been 
previously reported in subjects with CHD (ASD and VSDs).26,38 We 
identified a subject (case 26) with TOF with a 3.3 Mb gain involving 
TBX20 and an adjacent 4.7 Mb gain involving HOXA1, which has been 
reported in DECIPHER. Finally, we report a subject (case 32) with 
truncus arteriosus with a 1.8 Mb loss over the SALL4 gene, which has 
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not been previously reported. This segment included a loss over 
NFATC2, a regulator of cardiac transcription factors but was not 
included in our 100 gene list because likely causal variants have not 
previously been reported in humans in this gene.9 
Distribution of CNVs by subject.  
To characterize CHD study subjects with an approach more 
typically used in clinical genetics, CNVs were separated by size 
(whether or not they would be cytogenetically visible) and then the 
CHD WIKI site was employed to determine if remaining CNVs should 
be classified as involving a “syndromic” (two or more clinical features) 
or a “nonsyndromic” gene.1 Cytogenetically visible CNVs (category A) 
included chromosomal abnormalities ≥3 Mbps. This category contained 
subjects with Trisomy 21, 18; Turner; and XXX syndrome and 
represented ∼9% of the CHD cohort. Category B, contributing 6% to 
the overall CNV distribution, were those subjects with a CNV over a 
“syndromic-associated” CHD gene as reported by CHD WIKI.1 This 
subset contained 22qDS subjects (n = 42) with losses over the TBX1 
gene, William's Syndrome subjects, all with a phenotype of 
supravalvar aortic stenosis (n = 3) with losses over the ELN, 
GTF2IRD1, and FKBP6 genes. The “nonsyndromic” segment (category 
C) representing 1% of the CHD cohort was also defined by the CHD 
WIKI portal. Six CHD case subjects, contributing 1% to the total, had 
a CNV over one of the 100 CHD-associated genes; however, their 
category was considered unknown. Category E represented individuals 
with no CNV over our predefined 100 CHD risk gene list. An individual 
could only fit into one category where D>A>B or C (see Fig. 7). 
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Fig. 7. Distribution of CNVs in CHD cohort. Type A represents cytogenetically visible 
chromosomal abnormalities (≥3 Mbp), type B are those subjects with a CNV over a 
syndromic-associated CHD gene as reported by the CHD WIKI portal, type C are those 
recognized through CHD WIKI as nonsyndromic, type D are CNVs with an unknown 
category, and type E represents subjects with no CNV over our predefined 100 CHD-
associated genes. An individual can only fit into 1 category where D>A>B or C. 
Numbers are rounded to the nearest percentage. 
Complex CNVs.  
Four basic mechanisms are involved in the generation of a 
majority of CNVs: deletion, duplication, inversion, and related 
combinations.56 We were interested if CHD subjects were at increased 
risk for carrying multiple CNVs. In the current study, 125 CHD subjects 
were defined as complex (methods). We identified 100 of those with 
known CHD-associated syndromes (T21, 59; T18, 1; 22qDS, 31; 
Turner, 6; William's, 2; XXX Syndrome, 1). Of the remaining 25, 24 
contained likely causal CNVs for CHD as outlined in Table 5, whereas 
one subject contained a nonconfirmed CNV over a CHD-associated 
gene. Three complex subjects had CNVs on different chromosomes 
over two of our CHD associated genes of interest: subjects 2, 31, and 
33 (Table 5). In addition, two subjects from the CHD cohort were both 
syndromic with their additional CNV over a second gene of interest: a 
Turner syndrome subject had a gain involving the HRAS gene and a 
22qDS subject had an additional CNV involving a gain over the MAPK1 
gene. 
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It is interesting to note that applying the “complex” criteria to 
the MFHS control cohort also identified 10 subjects from the controls 
that met the complex analysis requirements. These subjects had gains 
over the genes FKBP6, MYH11, TERT, TBX1, CRKL, SH3PXD2B, and 
losses over the 1q21.1 gene region and MID1. 
Discussion 
CHD is a complex disease with demonstrated genetic etiology in 
a subset of patients. CNVs, viewed as an evolutionary driving force for 
new gene function resulting in improved survival and/or adaption to 
new environments and disease, contribute the largest component of 
natural human variation between any two individuals; indeed, CNVs 
contribute significantly more to inter-individual variation than 
SNPs.35,39,41 There is a broad range of CNV lengths. In this study we 
focused on large CNVs that can be detected with high accuracy and are 
relatively straightforward to confirm. It has previously been estimated 
that ∼65–80% of individuals have a large CNV (≥100 kb) and 
approximately three to seven CNV segments per individual.56 The 
average number of CNVs per subject in our CHD cohort supports these 
previous observations (Fig. 3). It is apparent that as CNV data 
continue to grow, the development of higher-resolution approaches 
will permit smaller CNV detection with better accuracy. This will 
potentially lead to additional disease association discoveries.23 
However, data suggest that common CNVs (CNPs) are likely to be 
lower penetrance risk factors, whereas rare CNV variants are more 
likely to carry highly penetrant disease risk factors.13 
Significant challenges remain in CNV disease-association studies 
at both the platform and analysis levels.37 The relationship between 
phenotype and gene dosage is complex. Our study represents a 
comprehensive data curation and filtering of CNVs involving 100 
recognized CHD risk genes detected in a large, anatomically 
phenotyped CHD population. We employed a strict algorithm to 
determine frequencies of CNVs involving regions that encompassed 
these CHD risk genes. The algorithm employed was very similar to a 
recent recommendation by Breckpot et al.6 for determining if CNVs 
detected in CHD patients are clinically relevant; herein we performed a 
comparison against two different control populations and an analysis 
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primarily based on known chromosomal abnormalities and gene 
content rather than more commonly used CNV detection approaches 
that prioritize by size. CNVs over these predefined gene regions were 
then used to search for relationships between cardiac phenotype and 
gene dosage. 
The novel analytical approach described herein identified known 
causal chromosomal abnormalities (including T21, T18, 22qDS, 
Turner, William's, and XXX Syndromes), which represent 14% of CHD 
subjects in this study, similar to previous observations.36 Overall, this 
descriptive study suggests that (after excluding well-established causal 
chromosomal abnormalities) large, rare CNVs in 100 well-defined CHD 
risk genes confers significant risk of CHD and is likely etiologic in 4.3% 
of CHD cases, similar to previous observations.6 Cardiac 
subphenotypes showing the most significant (P ≤ 0.05) enrichment of 
large CNV events were aortic stenosis (valvar), AV canal (partial), 
AVSD with TOF, subaortic stenosis, TOF, and truncus arteriosus. CNV 
frequency spectra analysis identified enriched genes (P ≤ 0.05): 
losses: FKBP6, ELN, GTF2IRD1, GATA4, CRKL, TBX1, ATRX, GPC3, 
BCOR, ZIC3, FLNA, and MID1; and gains: PRKAB2, FMO5, CHD1L, 
BCL9, ACP6, GJA5, HRAS, GATA6, and RUNX1. 1q21.1 gains were 
enriched in subjects with conotruncal defects and coarctation of the 
aorta. 8p23.1 losses were enriched in subjects with septal defects and 
gains involving HRAS were observed in subaortic stenosis and DILV. 
Cardiovascular malformations are known to be related to Ras/MAPK 
pathway syndromes and previous literature findings have reported 
associations of HRAS mutations resulting in increased hRAS signaling 
with the subaortic stenosis phenotype. Other common phenotypes 
occurring in patients with hRAS mutations (also known as Costello 
syndrome) are cardiac hypertrophy (usually typical hypertrophic 
cardiomyopathy) and arrhythmia (usually supraventricular tachycardia, 
especially chaotic atrial rhythm/multifocal atrial tachycardia or ectopic 
atrial tachycardia).43 Although DILV sometimes are associated with 
pulmonary stenosis we have not found any previous reports of hRAS 
mutations linked to this phenotype. Thus, our data appear to expand 
phenotypes related to the Ras/MAPK pathway. 
We hypothesized that CNV frequency spectra combined with 
detailed anatomic classes would define the impact of gene dosage in 
etiologic molecular pathways. One set of clues when searching for 
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genetic causes of CHD is given by the enrichment of CHD cases in 
various recognized causal chromosomal abnormalities such as T21, 
T18, 22qDS, Turner syndrome, and William's Syndrome.36 For 
instance, three of four (75%) subjects in our study with supravalvar 
aortic stenosis had deletions involving FKBP6, ELN, and GTF2IRD1 
genes; all of these subjects had William's syndrome. In Turner 
syndrome, the incidence of CHD can be as high as 50% and include 
phenotypes such as BAV, CoA, ASD-VSD partially anomalus pulmonary 
vena cava, and HLHS, but these data vary.4 The specific cause for CHD 
in patients with Turner syndrome is currently unknown; several genes 
have been implicated but for the most part do not quite match Turner 
syndrome phenotypes or have only been associated with the syndrome 
by animal models.4,5 In the present study, eight Turner syndrome 
subjects were easily identified from the total CHD cohort by CNV 
frequency spectra analysis. In these subjects, copy number losses 
were present on all six of the Chr. X genes (MID1, BCOR, ATRX, GPC3, 
ZIC3, and FLNA) that were selected as CHD-associated from our list of 
100 genes. Two out of eight Turner cases in the study had HLHS, five 
had coarctation of the aorta, and one had aortic stenosis (valvar). 
Turner syndrome-associated phenotype percentages for the CHD 
cohort were in good agreement with published reports.4 
To test for additional CNV gene enrichment with increased 
power, subphenotypes associated with T21, 22qDS, and Turner 
Syndrome were collapsed in these groups, respectively. The three 
collapsed groups of subphenotypes each demonstrated enrichment (P 
≤ 0.05) in additional CNVs compared with both control cohorts. Large, 
rare CNVs significantly increased (P ≤ 0.05) in the groups of T21 
subphenotypes included gains over GATA6 and RUNX1 and losses over 
GATA4, SOX7, TBX1 and CRKL. Likewise, collapsing the HLHS, CoA, 
and AS (valvar) subphenotypes that made up the Turner syndrome 
group indicated significant gains over the 1q21.1 gene regions, 
enriched losses over the Chromosome X genes, as well as gains over 
likely etiologic genes such as GATA4, SOX7, EHMT1, and HRAS and 
losses over FOXC1 and NOTCH1. Although the T21 and 22qDS 
collapsed groups share some overlap of phenotypes, it is interesting to 
note that the 22qDS grouping also included gains over the 1q21.1 
genes, as well as GATA6 and RUNX1. Significant CNV losses within the 
22qDS subclasses were over TBX1 and CRKL. Incorporating gene 
dosage with detailed phenotyping into current molecular cardiogenesis 
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models may allow future models of development to fine tune and 
increase our understanding of etiologic pathways. 
By narrowing our focus on a select set of 100 well-known CHD 
risk genes, we limited the study by design. We focused on large rare 
CNVs in the current study; therefore, smaller CNVs have not yet been 
examined. Furthermore, the number of subjects per phenotype was 
small because of detailed anatomic groupings; collapsing into fewer 
groups (with larger n) according to developmental models would 
increase power and may permit identification of additional enriched 
genes. An additional foreseeable limitation was that CNVs may have 
been enriched in genes, but because the analysis required statistical 
significance with two control cohorts (where CNVs were not confirmed 
and may have been inflated and manifested as false positives), the 
study may not have been sufficiently powered to detect smaller but 
true differences. 
To our knowledge, this is the first paper to curate a large and 
diverse CHD population with regard to subphenotype and CNV 
frequency by gene region. This appears to be a useful approach to 
visualize and eventually, given sufficient numbers, to quantify relative 
risk of CNVs for specific subphenotypes. Broadening to encompass the 
entire genome and performing the copy number spectra analysis at 
higher resolution should identify additional candidate genes in CHD. 
The ability to quantify risk of particular cardiac malformations by gene 
dosage should offer insight into critical molecular pathways impacted 
during human cardiogenesis. Furthermore, overlaying CNV data and 
details of resulting cardiac phenotype with known functional pathways 
of cardiogenesis should lead to increased understanding of the 
molecular etiology of heart malformations. 
Grants 
This study was supported in part by National Institutes of Health (NIH) Grant 
NIH1R21HD-060309-01 (A. Tomita-Mitchell), the CRI (A. Tomita-Mitchell and 
M. E. Mitchell), the Department of Surgery (A. Tomita-Mitchell, J. S. Tweddell, 
M. E. Mitchell), and in part by NIH Grant NIH5R01HL-089655 (U. Broeckel). 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 




A. Tomita-Mitchell, M. E. Mitchell, and C. A. Struble have conflicts of interest 
(significant financial interest in Aria Diagnostics, a molecular diagnostics 
company). M. Hidestrand and M. A. Goetsch have conflicts of interest 
(financial interest in Aria Diagnostics, a molecular diagnostics company). 
Author Contributions 
Author contributions: A.T.-M., D.K.M., S.E.H., D.P.B., U.B., A.N.P., J.S.T., and 
M.E.M. conception and design of research; A.T.-M., D.K.M., C.A.S., M.E.T., 
K.D.S., M.H., S.E.H., M.A.G., P.M.S., D.P.B., U.B., A.N.P., and M.E.M. 
analyzed data; A.T.-M., D.K.M., C.A.S., M.E.T., K.D.S., M.H., P.M.S., D.P.B., 
A.N.P., J.S.T., and M.E.M. interpreted results of experiments; A.T.-M., D.K.M., 
M.E.T., K.D.S., M.A.G., and P.M.S. prepared figures; A.T.-M., D.K.M., M.E.T., 
M.H., P.M.S., and M.E.M. drafted manuscript; A.T.-M., D.K.M., C.A.S., M.E.T., 
K.D.S., M.H., S.E.H., M.A.G., P.M.S., D.P.B., U.B., A.N.P., and M.E.M. edited 
and revised manuscript; A.T.-M., D.K.M., C.A.S., M.E.T., K.D.S., M.H., S.E.H., 
M.A.G., P.M.S., D.P.B., U.B., A.N.P., J.S.T., and M.E.M. approved final version 
of manuscript; D.K.M., D.P.B., and U.B. performed experiments. 
Acknowledgments 
First and foremost, we thank the families of the HHC from the 
CHW. We also acknowledge the significant contributions from the 
WPCR. We thank M. Krolikowski for excellent assistance with IRB 
contributions; the cardiothoracic surgical team including D. A. Jones, 
M. E. Barnes, J. L. Dunham-Ingle, T. A. Fehrenbacher, M. R. Madrzak, 
L. E. May, and R. G. Smith for research coordination; and the OR 
nursing staff for making this study possible. We gratefully 
acknowledge A. Klemm for assistance with the HHC database at CHW; 
the AGEN laboratory, especially R. B. Lorier, A. Mahter, A. Turner, B. 
Chirempes, and J. Wittke for technical assistance in the genetic 
laboratory; E. Semina for assistance in validations; S. Ghanta, J. 
Schroeder, A. Stoddard for helpful bioinformatic discussions; H. Liang 
for Tissue Bank support; and J. M. Routes, J. Lough, D. Beard, and B. 
Aronow for very helpful discussions and editing of this manuscript. 
Footnotes 
1The online version of this article contains supplemental material. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 




1 Barriot R, Breckpot J, Thienpont B, Brohee S, Van Vooren S, Coessens B, 
Tranchevent LC, Van Loo P, Gewillig M, Devriendt K, Moreau Y. 
Collaboratively charting the gene-to-phenotype network of human 
congenital heart defects. Genome Med 2: 16, 2010.  
2 Ben-Shachar S, Ou Z, Shaw CA, Belmont JW, Patel MS, Hummel M, Amato 
S, Tartaglia N, Berg J, Sutton VR, Lalani SR, Chinault AC, Cheung SW, 
Lupski JR, Patel A. 22q11.2 distal deletion: a recurrent genomic 
disorder distinct from DiGeorge syndrome and velocardiofacial 
syndrome. Am J Hum Genet 82: 214–221, 2008.  
3 Bittel DC, Butler MG, Kibiryeva N, Marshall JA, Chen J, Lofland GK, O'Brien 
JE., Jr Gene expression in cardiac tissues from infants with idiopathic 
conotruncal defects. BMC Med Genom 4: 1, 2011. 
4 Bondy CA. Congenital cardiovascular disease in Turner syndrome. Congenit 
Heart Dis 3: 2–15, 2008. 
5 Bondy CA, Cheng C. Monosomy for the X chromosome. Chromosome Res 
17: 649–658, 2009. 
6 Breckpot J, Thienpont B, Arens Y, Tranchevent LC, Vermeesch JR, Moreau Y, 
Gewillig M, Devriendt K. Challenges of interpreting copy number 
variation in syndromic and non-syndromic congenital heart defects. 
Cytogenet Genome Res 135: 251–259, 2011. 
7 Breckpot J, Thienpont B, Peeters H, de Ravel T, Singer A, Rayyan M, 
Allegaert K, Vanhole C, Eyskens B, Vermeesch JR, Gewillig M, 
Devriendt K. Array comparative genomic hybridization as a diagnostic 
tool for syndromic heart defects. J Pediatr 156: 810–817, 2011. 
8 Chan ISF. Exact tests of equivalence and efficacy with a non-zero lower 
bound for comparative studies. Statist Med 1403–1413, 1998 
9 Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, Graef IA, 
Crabtree GR. A field of myocardial-endocardial NFAT signaling 
underlies heart valve morphogenesis. Cell 118: 649–663, 2004. 
10 Chinn A, Fitzsimmons J, Shepard TH, Fantel AG. Congenital heart disease 
among spontaneous abortuses and stillborn fetuses: prevalence and 
associations. Teratology 40: 475–482, 1989. 
11 Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, Genesio R, D'Armiento 
M, Olla C, Paladini D, Zannini M, Nitsch L. Altered expression of 
mitochondrial and extracellular matrix genes in the heart of human 
fetuses with chromosome 21 trisomy. BMC Genomics 8: 268, 2007. 
12 Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA. Systematic 
assessment of copy number variant detection via genome-wide SNP 
genotyping. Nat Genet 40: 1199–1203, 2008.  
13 Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, 
Vukcevic D, Barnes C, Conrad DF, Giannoulatou E, Holmes C, Marchini 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
58 
 
JL, Stirrups K, Tobin MD, Wain LV, Yau C, Aerts J, Ahmad T, Andrews 
TD, Arbury H, Attwood A, Auton A, Ball SG, Balmforth AJ, Barrett JC, 
Barroso I, Barton A, Bennett AJ, Bhaskar S, Blaszczyk K, Bowes J, 
Brand OJ, Braund PS, Bredin F, Breen G, Brown MJ, Bruce IN, Bull J, 
Burren OS, Burton J, Byrnes J, Caesar S, Clee CM, Coffey AJ, Connell 
JM, Cooper JD, Dominiczak AF, Downes K, Drummond HE, Dudakia D, 
Dunham A, Ebbs B, Eccles D, Edkins S, Edwards C, Elliot A, Emery P, 
Evans DM, Evans G, Eyre S, Farmer A, Ferrier IN, Feuk L, Fitzgerald T, 
Flynn E, Forbes A, Forty L, Franklyn JA, Freathy RM, Gibbs P, Gilbert P, 
Gokumen O, Gordon-Smith K, Gray E, Green E, Groves CJ, Grozeva D, 
Gwilliam R, Hall A, Hammond N, Hardy M, Harrison P, Hassanali N, 
Hebaishi H, Hines S, Hinks A, Hitman GA, Hocking L, Howard E, 
Howard P, Howson JM, Hughes D, Hunt S, Isaacs JD, Jain M, Jewell 
DP, Johnson T, Jolley JD, Jones IR, Jones LA, Kirov G, Langford CF, 
Lango-Allen H, Lathrop GM, Lee J, Lee KL, Lees C, Lewis K, Lindgren 
CM, Maisuria-Armer M, Maller J, Mansfield J, Martin P, Massey DC, 
McArdle WL, McGuffin P, McLay KE, Mentzer A, Mimmack ML, Morgan 
AE, Morris AP, Mowat C, Myers S, Newman W, Nimmo ER, O'Donovan 
MC, Onipinla A, Onyiah I, Ovington NR, Owen MJ, Palin K, Parnell K, 
Pernet D, Perry JR, Phillips A, Pinto D, Prescott NJ, Prokopenko I, Quail 
MA, Rafelt S, Rayner NW, Redon R, Reid DM, Renwick Ring SM, 
Robertson N, Russell E, Clair D, Sambrook JG, Sanderson JD, 
Schuilenburg H, Scott CE, Scott R, Seal S, Shaw-Hawkins S, Shields 
BM, Simmonds MJ, Smyth DJ, Somaskantharajah E, Spanova K, Steer 
S, Stephens J, Stevens HE, Stone MA, Su Z, Symmons DP, Thompson 
JR, Thomson W, Travers ME, Turnbull C, Valsesia A, Walker M, Walker 
NM, Wallace C, Warren-Perry M, Watkins NA, Webster J, Weedon MN, 
Wilson AG, Woodburn M, Wordsworth BP, Young AH, Zeggini E, Carter 
NP, Frayling TM, Lee C, McVean G, Munroe PB, Palotie A, Sawcer SJ, 
Scherer SW, Strachan DP, Tyler-Smith C, Brown MA, Burton PR, 
Caulfield MJ, Compston A, Farrall M, Gough SC, Hall AS, Hattersley AT, 
Hill AV, Mathew CG, Pembrey M, Satsangi J, Stratton MR, Worthington 
J, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand 
W, Parkes M, Rahman N, Todd JA, Samani NJ, Donnelly P. Genome-
wide association study of CNVs in 16,000 cases of eight common 
diseases and 3,000 shared controls. Nature 464: 713–720, 2010. 
14 Cronk CE, Gangnon R, Cossette S, McElroy JA, Pelech AN. Modeling 
geographic risk of complex congenital heart defects in Eastern 
Wisconsin. Birth Defects Res A Clin Mol Teratol 91: 631–641, 2011. 
15 Erguler K. Barnard: Barnard's Unconditional Test. R package version 1.2. 
http://CRAN.R-project.org/package=Barnard  
16 Ferencz C, Correa-Villasenor A, Loffredo CA, Wilson PD. Malformations of 
the cardiac outflow tract. In: Genetic and Environmental Risk Factors 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
59 
 
of Major Cardiovascular Malformations: The Baltimore-Washington 
Infant Study: 1981–1989. Armonk: Futura Publishing, 1997, p. 59–
102 
17 Franklin RC, Jacobs JP, Tchervenkov CI, Beland MJ. Bidirectional crossmap 
of the Short Lists of the European Paediatric Cardiac Code and the 
International Congenital Heart Surgery Nomenclature and Database 
Project. Cardiol Young 12: 431–435, 2002. 
18 Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, 
Ergul E, Conta JH, Korn JM, McCarroll SA, Gorham JM, Gabriel S, 
Altshuler DM, Quintanilla-Dieck Mde L, Artunduaga MA, Eavey RD, 
Plenge RM, Shadick NA, Weinblatt ME, De Jager PL, Hafler DA, 
Breitbart RE, Seidman JG, Seidman CE. De novo copy number variants 
identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat 
Genet 41: 931–935, 2009. 
19 Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. Sex 
chromosome loss and aging: in situ hybridization studies on human 
interphase nuclei. Am J Hum Genet 57: 1143–1150, 1995.  
20 Harris S, Cronk C, Cassidy L, Simpson PM, Tomita-Mitchell A, Pelech AN. 
Exploring the environmental and genetic etiologies of congenital heart 
defects: the Wisconsin Pediatric Cardiac Registry. J Registry Manag 38: 
24–29, 2011. 
21 Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll 
Cardiol 39: 1890–1900, 2002. 
22 Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, 
Lee C. Detection of large-scale variation in the human genome. Nat 
Genet 36: 949–951, 2004. 
23 Itsara A, Cooper GM, Baker C, Girirajan S, Li J, Absher D, Krauss RM, Myers 
RM, Ridker PM, Chasman DI, Mefford H, Ying P, Nickerson DA, Eichler 
EE. Population analysis of large copy number variants and hotspots of 
human genetic disease. Am J Hum Genet 84: 148–161, 2009. 
24 Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, 
Warnes CA, Webb CL. Noninherited risk factors and congenital 
cardiovascular defects: current knowledge: a scientific statement from 
the American Heart Association Council on Cardiovascular Disease in 
the Young: endorsed by the American Academy of Pediatrics. 
Circulation 115: 2995–3014, 2007. 
25 Kathiriya IS, Srivastava D. Left-right asymmetry and cardiac looping: 
implications for cardiac development and congenital heart disease. Am 
J Med Genet 97: 271–279, 2000. 
26 Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, Castro ML, Butler TL, 
Hyun C, Guo G, Otway R, Mackay JP, Waddell LB, Cole AD, Hayward C, 
Keogh A, Macdonald P, Griffiths L, Fatkin D, Sholler GF, Zorn AM, 
Feneley MP, Winlaw DS, Harvey RP. Mutations in cardiac T-box factor 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
60 
 
gene TBX20 are associated with diverse cardiac pathologies, including 
defects of septation and valvulogenesis and cardiomyopathy. Am J 
Hum Genet 81: 280–291, 2007. 
27 Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K, Takahashi T, 
Matsuoka R, Yamagishi H. GATA6 mutations cause human cardiac 
outflow tract defects by disrupting semaphorin-plexin signaling. Proc 
Natl Acad Sci USA 106: 13933–13938, 2009.  
28 Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, 
Hubbell E, Veitch J, Collins PJ, Darvishi K, Lee C, Nizzari MM, Gabriel 
SB, Purcell S, Daly MJ, Altshuler D. Integrated genotype calling and 
association analysis of SNPs, common copy number polymorphisms 
and rare CNVs. Nat Genet 40: 1253–1260, 2008.  
29 Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, Baffa J, 
Hopkins E, Sol-Church K, Limongelli G, Digilio MC, Marino B, Innes AM, 
Aoki Y, Silberbach M, Delrue MA, White SM, Hamilton RM, O'Connor W, 
Grossfeld PD, Smoot LB, Padera RF, Gripp KW. Clinical, pathological, 
and molecular analyses of cardiovascular abnormalities in Costello 
syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A 155A: 
486–507, 2011 
30 Magri C, Sacchetti E, Traversa M, Valsecchi P, Gardella R, Bonvicini C, 
Minelli A, Gennarelli M, Barlati S. New copy number variations in 
schizophrenia. PLoS One 5: e13422, 2010. 
31 Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, 
McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, 
Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, 
Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, 
Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing 
heritability of complex diseases. Nature 461: 747–753, 2009.  
32 Momma K. Cardiovascular anomalies associated with chromosome 22q11.2 
deletion syndrome. Am J Cardiol 105: 1617–1624, 2010. 
33 Morgenthaler S, Thilly WG. A strategy to discover genes that carry multi-
allelic or mono-allelic risk for common diseases: a cohort allelic sums 
test (CAST). Mutat Res 615: 28–56, 2007. 
34 Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve 
HI, Beck AE, Tabor HK, Cooper GM, Mefford HC, Lee C, Turner EH, 
Smith JD, Rieder MJ, Yoshiura K, Matsumoto N, Ohta T, Niikawa N, 
Nickerson DA, Bamshad MJ, Shendure J. Exome sequencing identifies 
MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 42: 790–
793, 2010. 
35 Pang AW, MacDonald JR, Pinto D, Wei J, Rafiq MA, Conrad DF, Park H, 
Hurles ME, Lee C, Venter JC, Kirkness EF, Levy S, Feuk L, Scherer SW. 
Towards a comprehensive structural variation map of an individual 
human genome. Genome Biol 11: R52, 2010.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
61 
 
36 Pierpont ME, Basson CT, Benson DW, Jr, Gelb BD, Giglia TM, Goldmuntz E, 
McGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for 
congenital heart defects: current knowledge: a scientific statement 
from the American Heart Association Congenital Cardiac Defects 
Committee, Council on Cardiovascular Disease in the Young: endorsed 
by the American Academy of Pediatrics. Circulation 115: 3015–3038, 
2007. 
37 Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, Lionel AC, 
Thiruvahindrapuram B, Macdonald JR, Mills R, Prasad A, Noonan K, 
Gribble S, Prigmore E, Donahoe PK, Smith RS, Park JH, Hurles ME, 
Carter NP, Lee C, Scherer SW, Feuk L. Comprehensive assessment of 
array-based platforms and calling algorithms for detection of copy 
number variants. Nat Biotechnol 29: 512–520, 2011.  
38 Posch MG, Gramlich M, Sunde M, Schmitt KR, Lee SH, Richter S, Kersten A, 
Perrot A, Panek AN, Al Khatib IH, Nemer G, Megarbane A, Dietz R, 
Stiller B, Berger F, Harvey RP, Ozcelik C. A gain-of-function TBX20 
mutation causes congenital atrial septal defects, patent foramen ovale 
and cardiac valve defects. J Med Genet 47: 230–235, 2010. 
39 Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, 
Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, 
Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 
Large-scale copy number polymorphism in the human genome. 
Science 305: 525–528, 2004. 
40 Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O'Hara R, 
Casalunovo T, Conlin LK, D'Arcy M, Frackelton EC, Geiger EA, 
Haldeman-Englert C, Imielinski M, Kim CE, Medne L, Annaiah K, 
Bradfield JP, Dabaghyan E, Eckert A, Onyiah CC, Ostapenko S, Otieno 
FG, Santa E, Shaner JL, Skraban R, Smith RM, Elia J, Goldmuntz E, 
Spinner NB, Zackai EH, Chiavacci RM, Grundmeier R, Rappaport EF, 
Grant SF, White PS, Hakonarson H. High-resolution mapping and 
analysis of copy number variations in the human genome: a data 
resource for clinical and research applications. Genome Res 19: 1682–
1690, 2009. 
41 Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, Bejjani BA, Ou Z, 
Wiszniewska J, Driscoll DJ, Maisenbacher MK, Bolivar J, Bauer M, 
Zackai EH, McDonald-McGinn D, Nowaczyk MM, Murray M, Hustead V, 
Mascotti K, Schultz R, Hallam L, McRae D, Nicholson AG, Newbury R, 
Durham-O'Donnell J, Knight G, Kini U, Shaikh TH, Martin V, Tyreman 
M, Simonic I, Willatt L, Paterson J, Mehta S, Rajan D, Fitzgerald T, 
Gribble S, Prigmore E, Patel A, Shaffer LG, Carter NP, Cheung SW, 
Langston C, Shaw-Smith C. Genomic and genic deletions of the FOX 
gene cluster on 16q241 and inactivating mutations of FOXF1 cause 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
62 
 
alveolar capillary dysplasia and other malformations. Am J Hum Genet 
84: 780–791, 2009. 
42 Stevens KN, Hakonarson H, Kim CE, Doevendans PA, Koeleman BP, Mital S, 
Raue J, Glessner JT, Coles JG, Moreno V, Granger A, Gruber SB, 
Gruber PJ. Common variation in ISL1 confers genetic susceptibility for 
human congenital heart disease. PLoS One 5: e10855, 2010. 
43 Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, 
Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. A gene 
atlas of the mouse and human protein-encoding transcriptomes. Proc 
Natl Acad Sci USA 101: 6062–6067, 2004.  
44 Tartaglia NR, Howell S, Sutherland A, Wilson R, Wilson L. A review of 
trisomy X (47,XXX). Orphanet J Rare Dis 5: 8, 2010.  
45 Team RDC R: A Language and Environment for Statistical Computing. 
Vienna: R Foundation for Statistical Computing, http://www.R-
project.org, 2011 
46 Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans 
PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, 
Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene 
reprogramming in heart failure. Circulation 116: 258–267, 2007. 
47 Tomita-Mitchell A, Mahnke DK, Larson JM, Ghanta S, Feng Y, Simpson PM, 
Broeckel U, Duffy K, Tweddell JS, Grossman WJ, Routes JM, Mitchell 
ME. Multiplexed quantitative real-time PCR to detect 22q11.2 deletion 
in patients with congenital heart disease. Physiol Genomics 42A: 52–
60, 2010. 
48 van Engelen K, Postma AV, van de Meerakker JB, Roos-Hesselink JW, 
Helderman-van den Enden AT, Vliegen HW, Rahman T, Baars MJ, Sels 
JW, Bauer U, Pickardt T, Sperling SR, Moorman AF, Keavney B, 
Goodship J, Klaassen S, Mulder BJ. Ebstein's anomaly may be caused 
by mutations in the sarcomere protein gene MYH7. Neth Heart J [Epub 
ahead of print] 
49 Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, 
Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, 
Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg 
T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, 
Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, 
Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J. Rare structural 
variants disrupt multiple genes in neurodevelopmental pathways in 
schizophrenia. Science 320: 539–543, 2008. 
50 Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore 
SF, Schroth GP, Burge CB. Alternative isoform regulation in human 
tissue transcriptomes. Nature 456: 470–476, 2008.  
51 Wat MJ, Shchelochkov OA, Holder AM, Breman AM, Dagli A, Bacino C, 
Scaglia F, Zori RT, Cheung SW, Scott DA, Kang SH. Chromosome 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Physiological Genomics, Vol 44, No. 9 (May 1, 2012): pg. 518-541. DOI. This article is © American Physiological Society 
and permission has been granted for this version to appear in e-Publications@Marquette. American Physiological Society 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from American Physiological Society. 
63 
 
8p23.1 deletions as a cause of complex congenital heart defects and 
diaphragmatic hernia. Am J Med Genet A 149A: 1661–1677, 2009. 
52 Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. Loss of the Y 
chromosome: an age-related or clonal phenomenon in acute 
myelogenous leukemia/myelodysplastic syndrome? Arch Pathol Lab 
Med 132: 1329–1332, 2008. 
53 Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, 
Joo K, Kimura M, Imamura S, Kamatani N, Momma K, Takao A, 
Nakazawa M, Shimizu N, Matsuoka R. Role of TBX1 in human 
del22q11.2 syndrome. Lancet 362: 1366–1373, 2003. 
54 Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-
Even A, Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O. 
Genome-wide midrange transcription profiles reveal expression level 
relationships in human tissue specification. Bioinformatics 21: 650–
659, 2005. 
55 Yatsenko SA, Shaw CA, Ou Z, Pursley AN, Patel A, Bi W, Cheung SW, 
Lupski JR, Chinault AC, Beaudet AL. Microarray-based comparative 
genomic hybridization using sex-matched reference DNA provides 
greater sensitivity for detection of sex chromosome imbalances than 
array-comparative genomic hybridization with sex-mismatched 
reference DNA. J Mol Diagnost 11: 226–237, 2009. 
56 Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human 
health, disease, and evolution. Ann Rev Genom Hum Genet 10: 451–
481, 2009. 
57 Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of 
bioinformatics resources for display and analysis of copy number and 
other structural variants in the human genome. Cytogenet Genome 




Address for reprint requests and other correspondence: A. Tomita-Mitchell, 
Div. of Cardiothoracic Surgery, Dept. of Surgery, Medical College of 
Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226 (e-mail: 
amitchell@mcw.edu). 
 
 
